Healthcare >> CEO Interviews >> May 29, 2000
DR. JACK W. REICH, PhD is currently the Chief Executive Officer and
Chairman of the Board for Collateral Therapeutics, Inc. The company is a
leader in the field of cardiovascular gene therapy and went public in
July of 1998. Dr. Reich also co-founded MyoTech, Inc., a venture based
upon a novel clinical service model and drug therapy to treat chronic
muscle injury. That company was sold in 1996. Dr. Reich was also a
General Partner of Cabrillo Partners, a San Diego-based business
development company created to develop start-up and early-stage
companies focused in the areas of health care, medicine, biotechnology,
and life sciences. Prior to forming Cabrillo Partners, Dr. Reich was
Senior Vice President of Enterprise Partners, a successful, southern
California-based venture capital firm, and has played a key role in
developing biotech and medical technology companies. Prior to his career
in venture capital, Dr. Reich was Vice President, Regulatory Affairs and
Quality Operations, at Gensia, Inc., a biopharmaceutical company formed
to discover, develop, manufacture, and market novel pharmaceutical
products for the diagnosis and treatment of human disease. During his
long career in the pharmaceutical industry, Dr. Reich has had extensive
experience and interaction with regulatory bodies including the FDA, and
has been responsible for FDA approval and the successful introduction of
a broad range of new drugs. Dr. Reich has a Bachelor of Arts degree in
Biology from Washington and Jefferson College, a Bachelor of Science
degree in Pharmacy from Creighton University, a Master of Science degree
in Hospital Pharmacy Administration from Temple University, and a PhD in
Pharmaceuticals-International Pharmaceutical Administration from Temple
University. Profile
set the stage for readers?
Mr. Reich: Collateral Therapeutics is five years old. It's a
cardiovascular gene therapy
